To further confirm the antagonism between the IFNγ/JAK/STAT1 and JAK/STAT3 signalling pathways, we recorded the different levels of PD-L1 expression in NSCLC cell lines treated with or without IFNγ/STAT3 inhibitor by flow cytometry (Figures 6(a)–6(d)). The gene discussed is STAT3; the disease is non-small cell lung carcinoma.